Monitoring treatment and survival in chronic myeloid leukemia

Journal of Clinical Oncology

Volumn 17, Issue 6, 1999, Pages 1858-1868

  Baccarani, Michele ^a  

^a UNIVERSITY HOSPITAL OF UDINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; HYDROXYUREA; METHOTREXATE; RECOMBINANT ALPHA2A INTERFERON;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURVIVAL RATE;

EID: 0345188619     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.6.1858     Document Type: Article

References (71)

1. Galton DAG: Chemotherapy of chronic myelocytic leukemia. Semin Hematol 6:323-343, 1969
2. Tura S, Baccarani M, Zaccaria A: Chronic myeloid leukemia. Haematologica 71:169-176, 1986
3. Sokal JE, Baccarani M, Russo D, et al: Staging and prognosis in chronic myeloid leukemia. Semin Hematol 25:49-61, 1988
4. Talpaz M, Kantarjian HM, Kurzrock R, et al: Therapy of chronic myelogenous leukemia: Chemotherapy and interferons. Semin Hematol 25:62-73, 1988
5. Cervantes F, Robertson JE, Rozman C, et al: Long-term survivors in chronic granulocytic leukaemia: A study by the International CGL Prognosis Study Group. Br J Haematol 87:293-300, 1994
6. Doney K, Buckner D, Sale GE, et al: Treatment of chronic granulocytic leukemia by chemotherapy, total body irradiation and allogeneic bone marrow transplantation. Exp Hematol 6:738-747, 1978
7. Goldman JM, McCarthy DM, Hows JM, et al: Marrow transplantation for patients in the chronic phase of chronic granulocytic leukaemia. Lancet 2:623-625, 1982
8. Thomas ED, Clift RA, Fefer A, et al: Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 104:155-163, 1986
9. Goldman JM, Gale RP, Horowitz MM, et al: Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Ann Intern Med 108:806-814, 1988
10. Champlin RE, Goldman JM, Gale RP: Bone marrow transplantation in chronic myelogenous leukemia. Semin Hematol 25:74-80, 1988
11. Sullivan KM, Weiden PL, Storb R, et al: Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 73:1720-1728, 1989
12. Clift RA, Appelbaum FR, Thomas ED: Treatment of chronic myeloid leukemia by marrow transplantation. Blood 82:1954-1956, 1993
13. Gratwohl A, Hermans J, Niederwieser D, et al: Bone marrow transplantation for chronic myeloid leukemia: Long-term results. Bone Marrow Transplant 12:509-516, 1993
14. Clift RA, Buckner CD, Thomas ED, et al: Marrow transplantation for chronic myeloid leukemia: A randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 84:2036-2043, 1994
15. Silberman G, Crosse MG, Peterson EA, et al: Availability and appropriateness of allogeneic bone marrow transplantation for chronic myeloid leukemia in 10 countries. N Engl J Med 331:1063-1067, 1994
16. Kantarjian HM, O'Brien S, Anderlini P, et al: Treatment of chronic myelogenous leukemia: Current status and investigational options. Blood 87:3069-3081, 1996
17. McGlave P: Chronic leukemias, in Beatty PG (ed): Clinical and managed care issues in blood and marrow transplantation for hematologic diseases: Report of a symposium, 14 March 1996, Washington, DC. Exp Hematol 25:1195-1208, 1997
18. McGlave PB, Beatty P, Ash R, et al: Therapy for chronic myelogenous leukemia with unrelated donor bone marrow transplantation: Results in 102 cases. Blood 75:1728-1732, 1990
19. Marks DI, Cullis JO, Ward KN, et al: Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors: A comparison of complications in the first 2 years. Ann Intern Med 119:207-214, 1993
20. McGlave P, Bartsch G, Anasetti C, et al: Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: Initial experience of the National Marrow Donor Program. Blood 81:543-550, 1993
21. Aversa F, Tabilio A, Terenzi A, et al: Successful engraftment of T-cell-depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 84:3948-3955, 1994
22. Speiser DE, Hermans J, van Biezen A, et al: Haploidentical family member transplants for patients with chronic myeloid leukaemia: A report of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 19:1197-1203, 1997
23. Devergie A, Apperley JF, Labopin M, et al: European results of matched unrelated donor bone marrow transplantation for chronic myeloid leukemia: Impact of HLA class II matching. Bone Marrow Transplant 20:11-13, 1997
24. Dini G, Lamparelli T, Rondelli R, et al: Unrelated donor marrow transplantation for chronic myelogenous leukaemia. Br J Haematol 102:544-552, 1998
25. Hansen JA, Gooley TA, Martin PJ, et al: Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 338:962-968, 1998
26. Hehlmann R, Heimpel H, Hasford J, et al: Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: Prolongation of survival by hydroxyurea. Blood 82:398-407, 1993
27. Talpaz M, Kantarjian HM, McCredie K, et al: Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha in chronic myelogenous leukemia. N Engl J Med 314:1065-1068, 1986
28. Talpaz M, Kantarjian H, Kurzrock R, et al: Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Ann Intern Med 114:532-538, 1991
29. Ozer H, George SL, Schiffer CA, et al: Prolonged subcutaneous administration of recombinant alfa2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: Effect on remission duration and survival - Cancer and Leukemia Group B study 8583. Blood 82:2975-2984, 1993
30. Kantarjian HM, Smith TL, O'Brien S, et al: Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy: The Leukemia Service. Ann Intern Med 122:254-261, 1995
31. Italian Cooperative Study Group on Chronic Myeloid Leukemia: A prospective comparison of alpha-IFN and conventional chemotherapy in Ph+ chronic myeloid leukemia: Clinical and cytogenetic results at 2 years in 322 patients. Haematologica 77:204-214, 1992
32. Italian Cooperative Study Group on Chronic Myeloid Leukemia: Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 330:820-825, 1994
33. Hehlmann R, Heimpel H, Hasford J, et al: Randomized comparison of interferon-alfa, busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 84:4064-4077, 1984
34. Allan NC, Richards SM, Shepherd PCA on behalf of the UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia: UK Medical Research Council randomised, multicentre trial of interferon-alfa n1 for chronic myeloid leukaemia: Improved survival irrespective of cytogenetic response. Lancet 345:1392-1397, 1995
35. Ohnishi K, Ohno R, Tomonaga M, et al: A randomized trial comparing interferon-alfa with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 86:906-916, 1995
36. The German and Italian Chronic Myeloid Leukemia Study Groups Writing Committee (Hasford J, Baccarani M, Hehlmann R, et al): Interferon-alpha and hydroxyurea in early chronic myeloid leukemia: A comparative analysis of the Italian and German chronic myeloid leukemia trials with interferon-alpha. Blood 87:5384-5391, 1996
37. Chronic Myeloid Leukemia Trialists' Collaborative Group: Interferon alfa versus chemotherapy for chronic myeloid leukemia: A meta-analysis of seven randomized trials. J Natl Cancer Inst 89:1616-1620, 1997
38. Guilhot F, Chastang C, Michallet M, et al: Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 337:223-229, 1997
39. Medical Research Council's Working Party for Therapeutic Trials in Leukaemia: Chronic granulocytic leukaemia: Comparison of radiotherapy and busulphan therapy. BMJ 1:201-208, 1968
40. Medical Research Council's Working Party for Therapeutic Trials in Leukaemia: Randomized trial of splenectomy in Ph1-positive chronic granulocytic leukaemia, including an analysis of prognostic features. Br J Haematol 54:415-430, 1983
41. Italian Cooperative Study Group on Chronic Myeloid Leukemia: Results of a prospective randomized trial of early splenectomy in chronic myeloid leukemia. Cancer 54:333-338, 1984
42. Italian Cooperative Study Group on Chronic Myeloid Leukemia: Prospective confirmation of a prognostic classification for Ph+ chronic myeloid leukemia. Br J Haematol 69:463-466, 1988
43. Italian Cooperative Study Group on Chronic Myeloid Leukemia: Confirmation and improvement of Sokal's prognostic classification of Ph+ chronic myeloid leukemia: The value of early evaluation of the course of the disease. Ann Hematol 63:307-314, 1991
44. Italian Cooperative Study Group (ICSG) on Chronic Myeloid Leukemia: Karyotypic conversion by interferon as preparative treatment for autologous BMT in Ph positive CML. Leuk Lymphoma 11:277-280, 1993 (suppl 1)
45. Italian Cooperative Study Group on Chronic Myeloid Leukaemia: Evaluating survival after allogeneic bone marrow transplant for chronic myeloid leukaemia in chronic phase: A comparison of transplant versus no-transplant in a cohort of 258 patients first seen in Italy between 1984 and 1986. Br J Haematol 85:292-299, 1993
46. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in "Good-risk" chronic granulocytic leukemia. Blood 63:789-799, 1984
47. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized trials requiring prolonged observations in each patient: II. Analysis and examples. Br J Cancer 35:1-39, 1977
48. Cox DR: Regression models and life tables. J R Stat Soc 34:187-200, 1972
49. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
50. Mantel N, Byar DP: Evaluation of response-time data involving transient states: An illustration using heart-transplant data. J Am Stat Assoc 69:81-86, 1974
51. Goldman JM, Szydlo R, Horowitz MM, et al: Choice of pretransplant treatment and timing of transplant for chronic myelogenous leukemia in chronic phase. Blood 82:2235-2238, 1993
52. Anderson JR, Cain KC, Gelber RD: Analysis of survival by tumor response. J Clin Oncol 1:710-719, 1983
53. Gale RP, Hehlmann R, Zhang MJ, et al: Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. Blood 91:1810-1819, 1998
54. Beelen DW, Graeven U, Elmaagacli AH, et al: Prolonged administration of interferon-alpha in patients with chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome. Blood 85:2981-2990, 1995
55. Morton AJ, Gooley T, Hansen JA, et al: Impact of pre-transplant interferon-alpha on outcome of unrelated donor marrow transplants for chronic myeloid leukemia in first chronic phase. Proceedings of the 39th annual meeting of the American Society of Hematology. Blood 90:123a, 1997 (suppl 1, abstr 536)
56. Giralt SA, Kantarjian HM, Talpaz M, et al: Effect of prior interferon alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia. J Clin Oncol 11:1055-1061, 1993
57. Shepherd P, Richards S, Allan N: Survival after allogeneic bone marrow transplantation (BMT) in patients randomized into a trial of IFN alpha versus chemotherapy: No significant adverse effect of prolonged IFN alpha administration. Proceedings of the 37th annual meeting of the American Society of Hematology. Blood 86:94a, 1995 (suppl 1, abstr 363)
58. Horowitz MM, Giralt S, Szydlo R, et al: Effect of prior interferon therapy on outcome of HLA-identical sibling bone marrow transplants for chronic myelogenous leukemia (CML) in first chronic phase. Proceedings of the 38th annual meeting of the American Society of Hematology. Blood 88:682a, 1996 (suppl 1, abstr 2716)
59. Tomas JF, Lopez-Lorenzo JL, Requena MJ, et al: Absence of influence of prior treatment with interferon on the outcome of allogeneic bone marrow transplantation for chronic myeloid leukemia. Bone Marrow Transplant 22:47-51, 1998
60. Zuffa E, Bandini G, Bonini A, et al: Prior treatment with alpha-interferon does not adversely affect the outcome of allogeneic BMT in chronic phase chronic myeloid leukemia. Haematologica 83:231-236, 1998
61. McGlave PB, De Fabritiis P, Deisseroth A, et al: Autologous transplants for chronic myelogenous leukaemia: Results from eight transplant groups. Lancet 343:1486-1488, 1994
62. Kolb HJ, Mittermüller J, Clemm CH, et al: Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76:2462-2465, 1990
63. Kolb HJ, Schattenberg A, Goldman JM, et al: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86:2041-2050, 1995
64. Bacigalupo A, Soracco M, Vassallo F, et al: Donor lymphocyte infusion (DLI) in patients with chronic myeloid leukemia following allogeneic bone marrow transplantation. Bone Marrow Transplant 19:927-932, 1997
65. Bocchia M, Korontsvit T, Xu Q, et al: Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 87:3587-3592, 1996
66. ten Bosch GJA, Joosten AM, Kessler JH, et al: Recognition of bcr-abl positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a bcr-abl breakpoint peptide. Blood 88:3522-3527, 1996
67. Choudhyry A, Gajewski JL, Liang JC, et al: Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 89:1133-1142, 1997
68. Sacchi S, Kantarjian HM, Smith TL, et al: Early treatment decisions with interferon-alfa therapy in early chronic-phase chronic myelogenous leukemia. J Clin Oncol 16:882-889, 1998
69. Lee MS, Kantarjian H, Talpaz M, et al: Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome-positive chronic myelogenous leukemia following interferon therapy. Blood 79:1920-1923, 1992
70. Hochhaus A, Lin F, Reiter A, et al: Variable numbers of bcr-abl transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-alfa. Br J Haematol 91:126-131, 1995
71. Lee SJ, Kuntz KM, Horowitz MM, et al: Unrelated donor bone marrow transplantation for chronic myelogenous leukemia: A decision analysis. Ann Intern Med 127:1080-1088, 1997